LL, H., JS, E., JW, K., RM, H., G, A., A, B., . . . CG, S. (2025). Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024. The Pediatric infectious disease journal, 44(12), e464. https://doi.org/10.1097/INF.0000000000004942
Chicago Style (17th ed.) CitationLL, Hammitt, et al. "Nirsevimab Is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024." The Pediatric Infectious Disease Journal 44, no. 12 (2025): e464. https://doi.org/10.1097/INF.0000000000004942.
MLA (9th ed.) CitationLL, Hammitt, et al. "Nirsevimab Is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024." The Pediatric Infectious Disease Journal, vol. 44, no. 12, 2025, p. e464, https://doi.org/10.1097/INF.0000000000004942.
